Blueprint Medicines Corporation

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. We believe our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets.

Bank Name Blueprint Medicines Corporation
Stock Exchange NASDAQ
Symbol BPMC
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
CEO Mr. Jeffrey W. Albers
Employees 153
Registered Year 2008